

**INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT
SYNAGIS PRIOR AUTHORIZATION REQUEST FORM**



MDwise
Fax to: (858) 790-7100
c/o MedImpact Healthcare Systems, Inc.
Attn: Prior Authorization Department
10181 Scripps Gateway Court, San Diego, CA 92131
Phone: (800) 788-2949



Today's Date

/ /

Note: This form must be completed by the prescribing provider.

****All sections must be completed or the request will be returned****

Patient's Medicaid # <input type="text"/>	Date of Birth <input type="text"/> / <input type="text"/> / <input type="text"/>
Patient's Name	Prescriber's Name
Prescriber's IN License # <input type="text"/>	Specialty
Prescriber's NPI # <input type="text"/>	Prescriber's Signature
Return Fax # <input type="text"/> - <input type="text"/> - <input type="text"/>	Return Phone # <input type="text"/> - <input type="text"/> - <input type="text"/>
Check box if requesting retro-active PA <input type="checkbox"/>	Date(s) of service requested for retro-active eligibility (if applicable):

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

<p>1. Patient Information: Actual Gestational Age: _____ weeks _____ days Current Age (Must be < 24 months): _____ months Current Weight: _____ <input type="checkbox"/> kg <input type="checkbox"/> lb</p>
<p>2. Prescription Information: <input type="checkbox"/> Inject 15mg/kg IM once per month through March 31st <input type="checkbox"/> Other: _____</p>
<p>3. Palivizumab Prior Approval Criteria Guidelines for a maximum of 5 doses (Approval will be granted under any of the following circumstances):</p> <p><input type="checkbox"/> Infants < 12 months of age born preterm before 32 weeks gestation</p> <p><input type="checkbox"/> Infants < 12 months of age born with chronic lung disease (CLD) or bronchopulmonary dysplasia (BPD) (defined as: an oxygen requirement for at least 28 days after birth or those that developed an oxygen requirement) Please provide dates of oxygen supplementation: _____</p> <p><input type="checkbox"/> Infants < 12 months of age and requiring medical therapy for hemodynamically significant heart disease or cardiomyopathies Please provide relevant diagnoses/medication intervention: _____</p> <p><input type="checkbox"/> Infants < 12 months of age with neuromuscular disease or congenital abnormalities of the airways Please provide relevant diagnoses: _____</p>

- ☐ Infants and children < 24 months of age who required at least 28 days of supplemental oxygen after birth, and continue to require medical intervention (supplemental oxygen, chronic corticosteroid use, diuretic therapy)

Please provide dates of oxygen supplementation/medication intervention:

- ☐ Infants and children < 24 months of age who will be profoundly immunocompromised during the RSV season (solid organ or hematopoietic stem cell transplant, chemotherapy, or other condition that leaves the infant or child profoundly immunocompromised, including those awaiting heart transplant)

Please Explain:

- ☐ Infants and children < 24 months of age with evidence of hemodynamically significant coronary heart disease, cardiomyopathies, or pulmonary hypertension

Please Explain:

Note: *Prophylaxis will be given only until the infant or child reaches a maximum of 5 doses or the end of the RSV season, whichever comes first*

The Respiratory Syncytial Virus (RSV) season is defined as November 1st through March 31st. The Office of Medicaid Policy & Planning may extend the season based on statewide virology data. Administration of additional doses will require separate prior authorization. Please note that the criterion presented on the form pertains to the IHCP pharmacy benefit only.

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.